title: Complement activation fragment C5a receptors, CD88 and C5L2, are associated with neurofibrillary pathology.
abstract: BACKGROUND
  Alzheimer's disease (AD) is a neurodegenerative dementia characterized by the decline of cognition and the presence of neuropathological changes including neuronal loss, neurofibrillary pathology and extracellular senile plaques. A neuroinflammatory process is also triggered and complement activation has been hypothesized to have a relevant role in this local inflammatory response. C5a, a proinflammatory anaphylatoxin generated after complement activation, exerts its chemotactic and inflammatory functions through the CD88 receptor while the more recently discovered C5L2 receptor has been postulated to have an anti-inflammatory role. Previously, we reported that a CD88 specific antagonist (PMX205) decreased the pathology and improved cognition in transgenic models of AD suggesting that C5a/C5aR interaction has an important role in the progression of the disease.
  
  
  METHODS
  The present study characterizes the expression of the two receptors for C5a in human brain with confirmed post mortem diagnosis of vascular dementia (VD) or AD as well as age matched controls by immunohistochemistry and Western blot analysis using several antibodies against different epitopes of the human receptors.
  
  
  RESULTS
  The CD88 and C5L2 antibodies revealed increased expression of both receptors in AD samples as compared to age-matched controls or VD brain tissue by Western blot and immunohistochemistry, using multiple antibodies and distinct cohorts of brain tissue. Immunostaining showed that both the C5L2 and CD88 antibodies similarly labeled abundant neurofibrillary tangles, neuropil threads and dystrophic neurites associated with plaques in the hippocampus and frontal cortex of AD cases. In contrast, little or no neuronal staining, tangles or dystrophic neurites associated with plaques were observed in control or VD brains. CD88 and C5L2 receptors are associated with both early (AT8) and mature (PHF1) neurofibrillary tangles and can be found either independently or colocalized with each other.
  
  
  CONCLUSIONS
  The observed association of CD88 and C5L2 with neurofibrillary pathology suggests a common altered pathway of degradation.
authors: Dept of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697-3900, USA.
authors: Maria I
authors: MI
authors: Fonseca
authors: Susan O
authors: SO
authors: McGuire
authors: Scott E
authors: SE
authors: Counts
authors: Andrea J
authors: AJ
authors: Tenner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D015936:Complement C5a / Q000096:biosynthesis / Q000378:metabolism; D015140:Dementia, Vascular / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016874:Neurofibrillary Tangles / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine / Q000096:biosynthesis / Q000378:metabolism*; D011951:Receptors, Complement / Q000096:biosynthesis / Q000378:metabolism*
chemical_list: C488033:C5AR1 protein, human; C417003:C5aR2 protein, human; D044087:Receptor, Anaphylatoxin C5a; D019707:Receptors, Chemokine; D011951:Receptors, Complement; D015936:Complement C5a
references: Brain Pathol. 2012 Jan;22(1):99-109
references: 22150925
references: J Neurochem. 2001 Apr;77(1):43-9
references: 11279260
references: Mol Immunol. 2008 Aug;45(14):3767-74
references: 18635264
references: J Microsc. 2006 Dec;224(Pt 3):213-32
references: 17210054
references: Neuromolecular Med. 2010 Jun;12(2):179-92
references: 19763906
references: Am J Pathol. 1997 Jan;150(1):31-41
references: 9006319
references: Alzheimer Dis Assoc Disord. 2005 Apr-Jun;19(2):55-66
references: 15942322
references: J Neurol Sci. 1996 Dec;144(1-2):135-41
references: 8994115
references: J Immunol. 2001 Mar 15;166(6):4154-62
references: 11238666
references: Neurobiol Aging. 2000 May-Jun;21(3):383-421
references: 10858586
references: Neurosurgery. 2008 Jul;63(1):122-5; discussion 125-6
references: 18728577
references: J Neurosci Res. 1990 Sep;27(1):36-42
references: 2254955
references: Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):13-22
references: 11165367
references: J Immunol. 2003 Jun 1;170(11):5764-71
references: 12759460
references: FASEB J. 2006 Jul;20(9):1407-17
references: 16816116
references: J Neuroinflammation. 2012 Jun 21;9:137
references: 22721265
references: J Mol Med (Berl). 2009 Apr;87(4):375-8
references: 19189071
references: Mol Immunol. 2009 Sep;46(14):2753-66
references: 19477527
references: Cold Spring Harb Perspect Med. 2012 Aug 01;2(8):
references: 22908190
references: J Neuroinflammation. 2009 Nov 16;6:34
references: 19917081
references: J Neuroimmunol. 2009 May 29;210(1-2):52-62
references: 19286267
references: N Engl J Med. 2010 Jan 28;362(4):329-44
references: 20107219
references: J Immunol. 2009 Jul 15;183(2):1375-83
references: 19561098
references: Mol Immunol. 2011 Aug;48(14):1592-603
references: 21546088
references: J Biol Chem. 2010 Mar 5;285(10):7633-44
references: 20044484
references: Mol Immunol. 2009 Mar;46(6):1149-62
references: 19100624
references: J Neuroinflammation. 2012 Jul 23;9:179
references: 22824372
references: Trends Neurosci. 1999 Sep;22(9):397-402
references: 10441300
references: FASEB J. 2012 Sep;26(9):3680-90
references: 22651932
references: J Physiol. 1998 Mar 15;507 ( Pt 3):679-87
references: 9508829
references: Neurobiol Dis. 2004 Feb;15(1):40-6
references: 14751769
references: Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56(4):259-62
references: 2565620
references: Br J Pharmacol. 2007 Oct;152(4):429-48
references: 17603557
references: J Immunol. 1997 Jul 15;159(2):861-9
references: 9218605
references: J Exp Med. 1998 Aug 3;188(3):431-8
references: 9687521
references: J Immunol. 2008 Dec 15;181(12):8727-34
references: 19050293
references: J Neuropathol Exp Neurol. 2006 Jun;65(6):592-601
references: 16783169
references: J Biol Chem. 2005 Dec 2;280(48):39677-80
references: 16204243
references: J Neurochem. 2010 Apr;113(2):389-401
references: 20132482
references: Biochem J. 2003 Nov 1;375(Pt 3):503-15
references: 12959637
references: J Neurochem. 2003 Apr;85(1):115-22
references: 12641733
references: J Immunol. 1994 May 15;152(10):5050-9
references: 8176223
references: Science. 1987 Mar 27;235(4796):1641-4
references: 3029875
references: Adv Exp Med Biol. 2007;598:159-80
references: 17892211
references: J Neuroinflammation. 2008 Jan 29;5:5
references: 18230183
references: Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20
references: 1438191
references: Proc Natl Acad Sci U S A. 1987 May;84(9):3033-6
references: 3033674
references: J Neurochem. 2008 Sep;106(5):2080-92
references: 18624920
references: Nat Med. 2007 Apr;13(4):432-8
references: 17351623
references: FASEB J. 2013 Mar;27(3):855-64
references: 23239822
references: Exp Neurol. 1996 Mar;138(1):22-32
references: 8593893
references: Mol Immunol. 2010 Nov-Dec;48(1-3):219-30
references: 20813409
references: Glia. 2001 Jul;35(1):72-9
references: 11424194
references: J Neurochem. 2005 Mar;92(5):1140-9
references: 15715664
references: Neurobiol Aging. 1997 Jul-Aug;18(4):415-21
references: 9330973